Fibroblast growth factors in myocardial ischemia / reperfusion injury and ischemic preconditioning.


Angiogenic growth factors such as fibroblast growth factors (FGFs) are currently in clinical trials for accelerating blood vessel formation in myocardial and limb ischemic conditions. However, recent experimental evidence suggests that FGFs can also participate as endogenous cardioprotective agents. In this report, the current knowledge for FGFs implication… (More)


  • Presentations referencing similar topics